Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China.

Zhang XM, Li JX, Zhang GY, Li XH, Gu H.

BMC Gastroenterol. 2014 Jan 3;14:3. doi: 10.1186/1471-230X-14-3.

2.

[Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].

Zhang XH, Huang B, Wang JL, Li YH, Mi JM, Shen HT, Zhang ZG, Yan X, Xing LX, Wang SJ.

Zhonghua Zhong Liu Za Zhi. 2006 Jul;28(7):507-11. Chinese.

PMID:
17147114
3.

[Studies on the cut-off value of serum pepsinogen abnormality for screening chronic atrophic gastritis and gastric carcinoma].

Li YH, Zhang XH, Huang B, Wang JL, Mi JM, Shen HT, Zhang ZG, Yan X, Xing LX, Wang SJ.

Zhonghua Liu Xing Bing Xue Za Zhi. 2006 Oct;27(10):840-4. Chinese.

PMID:
17343174
4.

Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China.

Sun LP, Gong YH, Wang L, Yuan Y.

World J Gastroenterol. 2007 Dec 28;13(48):6562-7.

5.

[Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].

Gong YH, Sun LP, Yuan Y.

Zhonghua Zhong Liu Za Zhi. 2006 Sep;28(9):691-3. Chinese.

PMID:
17274377
6.

Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach.

Parthasarathy G, Maroju NK, Kate V, Ananthakrishnan N, Sridhar MG.

Trop Gastroenterol. 2007 Oct-Dec;28(4):166-70.

PMID:
18416347
7.

Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.

Huang Z, Zhang X, Lu H, Wu L, Wang D, Zhang Q, Ding H.

BMC Gastroenterol. 2014 Apr 11;14:74. doi: 10.1186/1471-230X-14-74.

8.

[Relationship between pepsinogen I/II ratio and age or upper gastrointestinal diseases in Helicobacter pylori-positive and -negative subjects].

Paik CN, Chung IS, Nam KW, Kwon JH, Chang JH, Suh JP, Park JM, Cho YK, Lee IS, Kim SW, Choi MG.

Korean J Gastroenterol. 2007 Aug;50(2):84-91. Korean.

9.

Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer.

Yun L, Bin Z, Guangqi G, Ding L, Xingdang L, Biao H.

Hepatogastroenterology. 2014 Jan-Feb;61(129):255-8.

PMID:
24895832
10.

Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, Shimosegawa T.

World J Gastroenterol. 2009 Feb 21;15(7):853-9.

11.
12.

[Potentialities of a serological method in diagnosis of atrophic gastritis].

Pimenov SI, Makarenko EV.

Ter Arkh. 2008;80(2):15-21. Russian.

PMID:
18372589
13.

Diagnostic values of serum levels of pepsinogens and gastrin-17 for screening gastritis and gastric cancer in a high risk area in northern Iran.

Nejadi-Kelarijani F, Roshandel G, Semnani S, Ahmadi A, Faghani B, Besharat S, Akhavan-Tabib A, Amiriani T.

Asian Pac J Cancer Prev. 2014;15(17):7433-6.

14.

[Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].

Chae H, Lee JH, Lim J, Kim M, Kim Y, Han K, Kang CS, Shim SI, Kim JI, Park SH.

Korean J Lab Med. 2008 Jun;28(3):201-6. doi: 10.3343/kjlm.2008.28.3.201. Korean.

15.

Serum pepsinogen II is a better diagnostic marker in gastric cancer.

Cao XY, Jia ZF, Jin MS, Cao DH, Kong F, Suo J, Jiang J.

World J Gastroenterol. 2012 Dec 28;18(48):7357-61. doi: 10.3748/wjg.v18.i48.7357.

16.

Validity of serum pepsinogen levels and quininium resin test combined for gastric cancer screening.

Kim JR, Lee K, Jung WT, Lee OJ, Kim TH, Kim HJ, Lee JS, Passaro DJ.

Cancer Detect Prev. 2005;29(6):570-5. Epub 2005 Nov 9.

PMID:
16289505
17.

The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis.

Kim EH, Kang H, Park CH, Choi HS, Jung DH, Chung H, Park JC, Shin SK, Lee SK, Lee YC.

Dig Liver Dis. 2015 Aug;47(8):663-8. doi: 10.1016/j.dld.2015.05.014. Epub 2015 May 23.

PMID:
26077884
18.

Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study.

So JB, Yeoh KG, Moochala S, Chachlani N, Ho J, Wong WK, Mack P, Goh PM.

Gastric Cancer. 2002;5(4):228-32.

PMID:
12491081
19.

Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions.

Shafaghi A, Mansour-Ghanaei F, Joukar F, Sharafkhah M, Mesbah A, Askari K, Geranmayeh S, Mehrvarz A, Souti F, Sokhanvar H, Fakhrieh S, Aminian K, Yousefi-Mashhour M, Khosh-Sorur M, Rasoulian J.

Asian Pac J Cancer Prev. 2013;14(6):3931-6.

20.

Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.

Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, Oka M, Watanabe M, Enomoto S, Niwa T, Maekita T, Iguchi M, Tamai H, Utsunomiya H, Yamamichi N, Fujishiro M, Iwane M, Takeshita T, Ushijima T, Ichinose M.

Int J Cancer. 2014 Mar 15;134(6):1445-57. doi: 10.1002/ijc.28470. Epub 2013 Oct 3.

Supplemental Content

Support Center